Merck announces safety, efficacy results from Phase 1 KANDLELIT-001 study

Merck (MRK), known as MSD outside of the United States and Canada, announced safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor, alone and in combination with other therapies in certain patients with KRAS G12C-mutant solid tumors, including advanced colorectal cancer and non-small cell lung cancer. In patients with advanced KRAS G12C-mutated CRC and NSCLC, a manageable safety profile and antitumor activity were observed with MK-1084 either as a monotherapy or in the combinations. Across all arms of the KANDLELIT-001 study, MK-1084 had a manageable safety profile. Treatment-related adverse events occurred in 58% of patients in the MK-1084 monotherapy arm, 94% of patients in the MK-1084 and KEYTRUDA arm, 93% of patients in the MK-1084 in combination with KEYTRUDA and chemotherapy arm, 95% of patients in the MK-1084 and cetuximab arm and 97% of patients in the MK-1084 with cetuximab and mFOLFOX6 arm.